Literatur
-
1
Vermeulen J, Aldenkamp A P.
Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research.
Epilespy Research.
1995;
22
65-9
-
2
Duncan J S, Shorvon S D, Trimble M R.
Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function.
Epilepsia.
1990;
31
584-591
-
3
Meador K J, Loring D W, Allen M E. et al .
Comparative cognitive effects of carbamazepine and phenytoin in healthy adults.
Neurology.
199;
41
1537-1540
-
4
Meador K J, Loring D W, Moore E E. et al .
Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults.
Neurology.
1995;
45
1494-1499
-
5
Sulzbacher S, Farwell J R, Temkin N. et al .
Late cognitive effects of early treatment with phenobarbital.
Clin Pedatr.
1999;
38
387-394
-
6
McGuire A M, Duncan J S, Trimble M R.
Effects of vigabatrin on cognitive functions and mood when used as add-on therapy in patients with intractable epilepsy.
Epilepsia.
1992;
33
128-134
-
7
Dodrill C B, Arnett J L, Sommerville K W. et al .
Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.
Neurology.
1993;
43
2501-2507
-
8
Dodrill C B, Arnett J L, Sommerville K W. et al .
Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy.
Neurology.
1997;
48
1025-1031
-
9
Grünewald R A, Thompson P J, Corcoran R. et al .
Effects of vigabatrin on partial seizures and cognitive function.
J Neurol Neurosurg Psychiatry.
1994;
57
1057-1063
-
10
Provinciali L, Bartolini M, Mari F. et al .
Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy.
Acta Neurol Scand.
1996;
94
12-18
-
11
Ylinen A, Kälviäinen R, Riekkinen P J.
Long-term efficacy and cognitive effects of vigabatrin.
Acta Neuro Scand.
1995;
Suppl 162
47-50
-
12
Cohen A F, Ashby L, Crowley D. et al .
Lamotrigine (BW430C), a potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam.
Br J Clin Pharmacol.
1985;
20
619-629
-
13
Martin R, Kuzniecky R, Ho S. et al .
Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.
Neurology.
1999;
52
321-327
-
14
Aldenkamp A P, Baker G.
A systematic review of the effects of lamotrigine on cognitive function and quality of life.
Epilepsy and Behavior.
2001;
2
85-91
-
15
Kälviäinen R, Äikiä M, Mervaala E. et al .
Long-term cognitive and EEG effects of tiagabine in drug-resistant parital epilepsy.
Epilepsy Research.
1996;
25
291-297
-
16
Dodrill C B, Arnett J L, Sommerville K W, Shu V.
Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy.
Epilepsy.
1997;
48
1025-1031
-
17
Dodrill C B, Arnett J L, Deaton R. et al .
Tiagabine versus phenytoin and carbamazepin as add-on therapies: effects on abilities, adjustment and mood.
Epilepsy Research.
2000;
42
123-132
-
18
Dodrill C B, Arnett J L, Shu V. et al .
Effects of tiagabine monotherapy on abilities, adjustment, and mood.
Epilepsia.
1998;
39
33-42
-
19
Leach J P, Girvan J, Paul A, Brodie M J.
Gabapentin and cognition: a double blind, dose ranging, placebo-controlled study in refractory epilepsy.
J Neurol Neurosurg Psychiatry.
1997;
62
372-376
-
20
Mortimore C, Trimble M, Emmer E.
Effects of gabapentin on cognition and quality of life in patients with epilepsy.
Seizure.
1998;
7
359-364
-
21
Dodrill C B, Arnett J L, Hayes A G. et al .
Cognitive abilities and adjustment with gabapentin: results of a multisite study.
Epilepsy Res.
1999;
35
109-121
-
22
Faught E, Wilder B J, Ramsay R E. et al .
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.
Neurology.
1996;
46
1684-1690
-
23
Aldenkamp A P, Baker G, Mulder O G. et al .
A randomized clinical study comparing the cognitive effects of topiramate versus valproate in a first-line add-on design.
Epilepsia.
1999;
40, Suppl 7
83-84
-
24
Aldenkamp A P.
Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.
Neurology.
2000;
54
271-272
-
25
Aldenkamp A P, Baker G, Mulder O G. et al .
A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.
Epilepsia.
2000;
41
1167-1178
-
26
Thompson P J, Baxendale S A, Duncan J S. et al .
Effects of topiramate on cognitive function.
J Neurol Neurosurg Psychiatry.
2000;
69
636-641
-
27
Huppertz H J, Quiske A, Schulze-Bonhage A.
Kognitive Beeinträchtigungen unter Add-on-Therapie mit Topiramat.
Nervenarzt.
2001;
72
275-280
-
28
Kessler R C, McGonagle K A, Zhao S. et al .
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United State. Results from the National Comorbidity Survey.
Arch Gen Psychiatry.
1994;
51
8-19
-
29
Anthony J C, Eaton W W, Henderson A S.
Looking to the future in psychiatric epidemiology.
Epidemiol Rev.
1995;
17
240-242
-
30 Helmstaedter C. Neuropsychologie bei Epilepsie. In: Sturm W, Herrmann M, Wallesch CW (Hrsg) Lehrbuch der Klinischen Neuropsychologie. Lisse; Swets & Zeitlinger 2000: 571-580
Dr. med. Ute Kopp
Neurologische Klinik und Poliklinik · Charité · Humboldt-Universität Berlin
Augustenburger Platz 1
13353 Berlin
